Chemotherapy Side Effects — What to Expect, What to Report

Neutropenic sepsis — infection occurring while your white cell count is low. Chemotherapy suppresses the bone marrow, and the count typically reaches its lowest around seven to fourteen days after each cycle. Critically, a low count produces no symptoms at all, so a fever during that window may be the only warning you get, and infection in that state can become life-threatening within hours. Call the twenty-four hour number immediately for a temperature, shivering or simply feeling suddenly unwell — at any hour, on any day, and without taking paracetamol first, because it masks the fever. Treatment is prompt intravenous antibiotics, and promptness determines the outcome.

Probably not, and this is one area where treatment has genuinely improved. Modern anti-sickness medication is highly effective, and severe vomiting through chemotherapy is no longer an expected part of the experience. The commonest reason women still suffer is taking the tablets only when they feel sick rather than on the schedule prescribed — these medicines work by prevention, and rescuing established nausea is much harder than preventing it. Take them as directed for the days after each cycle even if you feel fine. If nausea still breaks through, call, because there are several different classes and another will often work.

Because it is the one side effect where the timing of reporting changes whether it becomes permanent. Certain chemotherapy classes damage peripheral nerves, producing numbness, tingling or altered sensation in the fingers and toes, and the damage accumulates with each dose. Reported early, the dose can be reduced or the schedule changed, which prevents progression. Reported at the final cycle, the damage is already established, and established nerve damage recovers slowly and sometimes incompletely. Watch particularly for functional changes — difficulty with buttons, dropping things, unsteadiness — which indicate more than mild numbness.

Generally yes, and knowing this in advance prevents an unnecessarily demoralising conclusion. Effects tend to accumulate rather than staying level, so the final two cycles are usually harder than the first two, with fatigue in particular building steadily. This is expected behaviour rather than a sign that something is wrong or that the disease is progressing. It is also a reason to report tolerance problems early rather than at the end, while there is still time to adjust doses — dose reduction is a normal part of chemotherapy, and completing a reduced-dose course generally achieves more than abandoning a full-dose one halfway.

Yes, within reason, and this surprises people because the instinct is to rest. The strongest evidence for managing cancer-related fatigue supports graded physical activity rather than rest — short regular walks are enough to make a measurable difference, and activity also improves mood, sleep and appetite. Maintaining muscle also matters practically, because loss of weight and strength limits what treatment can be safely given. The exception is the low-count window, when it is sensible to avoid crowded gyms and anyone obviously unwell, though ordinary activity outdoors remains fine. The women who deteriorate most across a course are frequently those who stopped moving early.